Climb Bio to Host Virtual Investor Event on October 15, 2024

Rhea-AI Summary

Climb Bio (Nasdaq: CLYM) has announced a virtual investor event scheduled for October 15, 2024. The event will feature presentations from key management team members and an external expert, providing updates on the company's strategy and focus on developing therapeutics for immune-mediated diseases.

Presenters will include Aoife Brennan (President and CEO), Stephen Thomas (Board Member), Jan Hillson (Senior Clinical Advisor), Nishi Rampal (SVP of Clinical Development), Brett Kaplan (COO), and Frank Cortazar (Director of the New York Nephrology Vasculitis and Glomerular Center).

The event will offer an in-depth review of Climb Bio's lead asset, budoprutug, an anti-CD19 monoclonal antibody designed to treat various immune-mediated diseases. Budoprutug has shown B-cell depletion in early clinical trials. A live webcast and replay will be available on the company's website.

WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of Climb Bio’s management team and an external expert who will provide an update to the investment community on the Company’s strategy and focus on developing therapeutics for immune-mediated diseases.

Climb Bio’s virtual investor event will include presentations from Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer, Stephen Thomas, Ph.D., Member of Climb Bio’s Board and Co-founder of Tenet Medicines, Jan Hillson, M.D., Senior Clinical Advisor, Nishi Rampal, M.D., Senior Vice President, Clinical Development, and Brett Kaplan, M.D., Chief Operating Officer as well as presentations from a key opinion leader, Frank Cortazar, Director of the New York Nephrology Vasculitis and Glomerular Center.

The event will provide an in-depth review of Climb Bio’s lead asset, budoprutug, an anti-CD19 monoclonal antibody that is designed to treat a broad range of immune-mediated diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy and has demonstrated B-cell depletion in early clinical trials.

Register for the event here.

A live webcast of the event, as well as a replay, will be available under "Events and Presentations" in the Investors section of the Company's website: climbbio.com

About Climb Bio, Inc.
Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com.

Investors
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
339-970-2843

Media
Jon Yu
ICR Westwicke
jon.yu@westwicke.com
475-395-5375

FAQ

When is Climb Bio (CLYM) hosting its virtual investor event?

Climb Bio (CLYM) is hosting its virtual investor event on October 15, 2024.

What will be discussed at Climb Bio's (CLYM) virtual investor event?

The event will provide updates on Climb Bio's strategy, focus on developing therapeutics for immune-mediated diseases, and an in-depth review of their lead asset, budoprutug.

Who are the key presenters at Climb Bio's (CLYM) upcoming investor event?

Key presenters include Aoife Brennan (CEO), Stephen Thomas (Board Member), Jan Hillson (Senior Clinical Advisor), Nishi Rampal (SVP Clinical Development), Brett Kaplan (COO), and Frank Cortazar (external expert).

What is budoprutug, Climb Bio's (CLYM) lead asset?

Budoprutug is an anti-CD19 monoclonal antibody designed to treat a broad range of immune-mediated diseases, including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy.

How can investors access Climb Bio's (CLYM) virtual investor event?

Investors can register for the event through a provided link, and a live webcast and replay will be available on Climb Bio's website under 'Events and Presentations' in the Investors section.